NCT04040205View on ClinicalTrials.gov

Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

PHASE2RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 7, 2019

Primary Completion Date

June 1, 2027

Study Completion Date

June 1, 2027

Conditions
ChondrosarcomaOsteosarcomaSoft Tissue Sarcoma
Interventions
DRUG

Abemaciclib

Abemaciclib 200 mg will be taken by mouth twice daily.

Trial Locations (4)

32224

RECRUITING

Mayo Clinic, Jacksonville

52242

RECRUITING

University of Iowa Hospitals and Clinics, Iowa City

53226

RECRUITING

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

63130

RECRUITING

Washington University in St. Louis, St Louis

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER